SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface
modification and in vitro diagnostic technologies to the healthcare
industries, today announced the appointment of Andy LaFrence as the
company’s Vice President of Finance and Chief Financial Officer,
effective February 12, 2013. He will lead all of the financial
activities of SurModics, including controlling, financial planning and
analysis, treasury, tax, audit and investor relations. LaFrence will
succeed Timothy Arens, who currently serves as interim Chief Financial
Officer. Arens will remain with the company and will transition into the
role of Vice President of Corporate Development and Strategy. In his new
role, Mr. Arens will lead the company’s efforts in developing strategies
and assessing growth opportunities for its Medical Device and In Vitro
Diagnostics businesses.
“Andy will be a tremendous addition to our executive team,” said Gary
Maharaj, President and Chief Executive Officer, noting that “his
extensive financial experience, sound business judgment, leadership and
strong knowledge of the medical device and healthcare space will help
guide SurModics through our next stage of growth. I would also like to
thank Tim for all of his exemplary work as interim Chief Financial
Officer and look forward to his continuing contributions to SurModics’
success in this important new role.”
LaFrence is a certified public accountant and has over 25 years of
finance and management experience. Most recently, he served as Chief
Financial Officer of CNS Therapeutics, which was recently acquired by
Covidien. Prior to that, he was an audit partner at KPMG, where he
focused on supporting public and private, high-growth medical
technology, pharmaceutical and biotechnology companies.
About SurModics, Inc.
SurModics’ mission is to exceed our customers’ expectations and enhance
the well-being of patients by providing the world’s foremost, innovative
surface modification technologies and in vitro diagnostic chemical
components. The Company partners with the world’s leading and emerging
medical device, diagnostic and life science companies to develop and
commercialize innovative products designed to improve patient diagnosis
and treatment. Core offerings include surface modification coating
technologies that impart lubricity, prohealing, and biocompatibility
capabilities; and components for in vitro diagnostic test kits and
microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For
more information about the Company, visit http://www.surmodics.com.
The content of SurModics’ website is not part of this press release or
part of any filings that the Company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that
are not historical or current facts, including statements about beliefs
and expectations regarding our strategies and ability to achieve our
growth plans, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties, and important factors could
cause actual results to differ materially from those anticipated,
including the factors identified under "Risk Factors" in Part I, Item 1A
of our Annual Report on Form 10-K for the fiscal year ended September
30, 2012, and updated in our subsequent reports filed with the SEC.
These reports are available in the Investors section of our website at www.surmodics.com
and at the SEC website at www.sec.gov.
Forward-looking statements speak only as of the date they are made, and
we undertake no obligation to update them in light of new information or
future events.
